Lack of Gilead and BMS teamwork on hep C draws ire

Gilead Sciences' ($GILD) reluctance to strike a collaboration deal with Bristol-Myers Squibb ($BMY) on a combo hepatitis C treatment has ruffled some feathers in the clinical community, after a small study showed that the companies' drugs worked well together in combating the liver-damaging disease. "The only appropriate motivation should be what is the best and fastest way to get cures, not what is best for the shareholders," Dr. Scott Friedman, chief of liver diseases at the Mount Sinai School of Medicine in New York, told The New York Times. Article

Suggested Articles

The deal gives J&J a stake in the development and commercialization of anticoagulants including phase 2-ready secondary stroke candidate BMS-986177.

Boehringer gained the global rights to OSE's SIRP-alpha antagonist, which is in development for solid tumors.

Lilly is diving into encapsulated beta cell treatments, designed to restore insulin production in patients with Type 1 diabetes.